Management of malignant pleural effusion secondary to breast cancer: talc pleurodesis and pleuroperitoneal shunting
- PMID: 7744586
Management of malignant pleural effusion secondary to breast cancer: talc pleurodesis and pleuroperitoneal shunting
Abstract
Malignant pleural effusion is a frequent complication of metastatic breast cancer, leading to a significant degree of morbidity. Drainage of the effusion by thoracocentesis and subsequent pleurodesis is an established means of symptomatic relief in these patients. Several sclerosing agents have been reported in the literature, including doxycylin, minocyclin, tetracyclines, bleomycin, cisplatin, etoposide, fluorouracil, interferon-beta, Corynebacterium parvum, and talc which gives the best results. The condition of the lung's parenchyma must be evaluated prior to the procedure to rule out lymphangitis carcinomatosa or bronchial obstruction that would impair the expansion of the lung. In these situations, the implantation of a pleuroperitoneal shunt is an alternative to be considered.
Similar articles
-
Video-assisted management of malignant pleural effusion in breast carcinoma.Cancer. 2006 Jan 15;106(2):271-6. doi: 10.1002/cncr.21623. Cancer. 2006. PMID: 16342163
-
[Current treatment strategy in malignant pleural effusion].Wien Klin Wochenschr. 1996;108(9):255-61. Wien Klin Wochenschr. 1996. PMID: 8686317 Review. German.
-
[Treatment of malignant pleural effusion by pleurodesis with talc].Chir Ital. 2000 Sep-Oct;52(5):541-7. Chir Ital. 2000. PMID: 11190547 Italian.
-
[Talc--a standard drug in the treatment of malignant pleural effusion].Cas Lek Cesk. 1999 Jan 25;138(3):82-4. Cas Lek Cesk. 1999. PMID: 10376391 Czech.
-
Pleural malignancies.Curr Opin Pulm Med. 1996 Jul;2(4):335-40. Curr Opin Pulm Med. 1996. PMID: 9363162 Review.
MeSH terms
Substances
LinkOut - more resources
Medical